Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leonard

Showing results (441-450 of 686) with videos related to

Pageof 69
Sort By:
Palliative & Supportive Care|June 17, 2022
Unmet mental health needs in patients with advanced B-cell lymphomasChrystal Marte, Login S George, Sarah C Rutherford, et al.
Annals of the Royal College of Surgeons of England|April 26, 2001
Neo-adjuvant therapy improves resectability rates for colorectal liver metastasesA Shankar, P Leonard, A J Renaut, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 1996
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11R G Hawley, T S Hawley, A Z Fong, et al.
Blood|August 15, 2002
Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responsesKyriaki Dunussi-Joannopoulos, Krystyna Zuberek, Kathlene Runyon, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Cancer|March 15, 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapyMorton Coleman, Peter Martin, Jia Ruan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Nucleic Acids Research|June 1, 2023
Prolonging genetic circuit stability through adaptive evolution of overlapping genesJennifer L Chlebek, Sean P Leonard, Christina Kang-Yun, et al.
Pageof 69

Showing results (441-450 of 686) with videos related to

Sort By:
Pageof 69
Palliative & Supportive Care|June 17, 2022
Unmet mental health needs in patients with advanced B-cell lymphomasChrystal Marte, Login S George, Sarah C Rutherford, et al.
Annals of the Royal College of Surgeons of England|April 26, 2001
Neo-adjuvant therapy improves resectability rates for colorectal liver metastasesA Shankar, P Leonard, A J Renaut, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 1996
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11R G Hawley, T S Hawley, A Z Fong, et al.
Blood|August 15, 2002
Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responsesKyriaki Dunussi-Joannopoulos, Krystyna Zuberek, Kathlene Runyon, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Leukemia & Lymphoma|January 24, 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphomaRebecca L Elstrom, Biree Andemariam, Peter Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Cancer|March 15, 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapyMorton Coleman, Peter Martin, Jia Ruan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Nucleic Acids Research|June 1, 2023
Prolonging genetic circuit stability through adaptive evolution of overlapping genesJennifer L Chlebek, Sean P Leonard, Christina Kang-Yun, et al.
Pageof 69